New drug duo aims to shrink hard-to-treat colon cancer
NCT ID NCT05382442
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two experimental drugs, AK112 and AK117, alone or together, in people with metastatic colorectal cancer that cannot be removed with surgery. The goal is to see if the drugs can shrink tumors or slow the disease. About 254 participants will be enrolled, and the study will monitor side effects and how long any benefits last.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Summit Therapeutics Research Site
Los Angeles, California, 90067, United States
-
Summit Therapeutics Research Site
Murrieta, California, 92562, United States
-
Summit Therapeutics Research Site
Fairfax, Virginia, 22031, United States
-
The Sixth Hospital,Sun Yat-sen University
Guanzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?